| Rx0000345 |
Cetylite Industries |
03/31/2021 |
10223020202 |
CetacaineAnesthetic Liquid 14g |
01/01/2021 |
24.05 |
105.30 |
None |
Non-innovator Multiple Source Drug |
8690 |
None |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000345 |
Cetylite Industries |
03/31/2021 |
10223020204 |
CetacaineAnesthetic Liquid 30g |
01/01/2021 |
27.20 |
165.10 |
None |
Non-innovator Multiple Source Drug |
17093 |
None |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000345 |
Cetylite Industries |
03/31/2021 |
10223020103 |
CetacaineAnesthetic Spray 20g |
01/01/2021 |
17.55 |
75.40 |
None |
Non-innovator Multiple Source Drug |
85156 |
None |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000139 |
Chiesi USA |
03/31/2021 |
10122051001 |
Curosurf® 1.5ml, 80 mg/ml poractant alfa |
02/06/2021 |
36.58 |
493.88 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chieisi USA believes is otherwise in the public domain or publicly available. (2) Columns N-T were intentionally left blank for this submission, as the drug was not acquired. |
| Rx0000139 |
Chiesi USA |
03/31/2021 |
10122051003 |
Curosurf® 3.0ml, 80 mg/ml poractant alfa |
02/06/2021 |
72.14 |
973.88 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chieisi USA believes is otherwise in the public domain or publicly available. (2) Columns N-T were intentionally left blank for this submission, as the drug was not acquired. |
| Rx0000139 |
Chiesi USA |
03/31/2021 |
52609000601 |
Ferriprox film-coated tablets 500mg 100ct |
01/04/2021 |
343.61 |
7215.73 |
06/28/2021 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/06/2020 |
ApoPharma Inc. |
None |
1 |
No comment. |
6363.07 |
5843.04 |
2011 |
3168.00 |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chieisi USA believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of March 31, 2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. |
| Rx0000139 |
Chiesi USA |
03/31/2021 |
52609000705 |
Ferriprox film-coated tablets three-a-day 1000mg 50 ct |
01/04/2021 |
343.61 |
7215.73 |
06/28/2021 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/06/2020 |
ApoPharma Inc. |
None |
1 |
No comment. |
6363.07 |
5843.04 |
2011 |
3168.00 |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chieisi USA believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of March 31, 2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. |
| Rx0000139 |
Chiesi USA |
03/31/2021 |
52609450207 |
Ferriprox Solution for oral use 100mg/ml 500ml bottle |
01/04/2021 |
343.61 |
7215.73 |
10/20/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/06/2020 |
ApoPharma Inc. |
None |
1 |
No comment. |
6363.07 |
5843.04 |
2015 |
4533.00 |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chieisi USA believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of March 31, 2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. |
| Rx0000358 |
Civica, Inc |
03/31/2021 |
72572025025 |
Heparin Sodium Injection Solution 1000 Unit/ML Vial Qty 25 |
02/01/2021 |
9.25 |
43.50 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
11/15/2019 |
Hikma |
0 |
1 |
Civica is selling under a non-exclusive license through a product supply agreement with the manufacturer (Hikma). There was no licensing fee, or acquisition price, only a fee per unit purchased from the manufacturer (Hikma). |
34.25 |
34.25 |
2011 |
65.50 |
None |
Civica does not own patent for this product. The information for the year_ introduced and WAC_ at_ introduction was sourced from Medi-Span for NDC 00641-0391-12 on April 28, 2021. |
| Rx0000358 |
Civica, Inc |
03/31/2021 |
72572025525 |
Heparin Sodium Injection Solution 5000 Unit/ML Vial Qty 25 |
02/01/2021 |
9.25 |
43.50 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
11/15/2019 |
Hikma |
0 |
1 |
Civica is selling under a non-exclusive license through a product supply agreement with the manufacturer (Hikma). There was no licensing fee, or acquisition price, only a fee per unit purchased from the manufacturer (Hikma). |
34.25 |
34.25 |
2011 |
65.50 |
None |
Civica does not own patent for this product. The information for the year_ introduced and WAC_ at_ introduction was sourced from Medi-Span for NDC 00641-0391-12 on April 28, 2021. |
| Rx0000030 |
Clovis Oncology, Inc |
06/30/2021 |
69660020191 |
Rubraca 200mg, 60 tabs/bottle |
04/01/2021 |
334.00 |
8685.00 |
08/17/2035 |
Single Source Drug |
3458 |
None |
Manufacturing costs, inflation costs, and market dynamics allow the increase to remain within market value |
None |
No change improvements |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=546, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=549 |
Product licensing was not acquired within the last 5 years. |
| Rx0000030 |
Clovis Oncology, Inc |
06/30/2021 |
69660020291 |
Rubraca 250mg, 60 tabs/bottle |
04/01/2021 |
334.00 |
8685.00 |
08/17/2035 |
Single Source Drug |
2822 |
None |
Manufacturing costs, inflation costs, and market dynamics allow the increase to remain within market value |
None |
No change improvements |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=547, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=550 |
Product licensing was not acquired within the last 5 years. |
| Rx0000030 |
Clovis Oncology, Inc |
06/30/2021 |
69660020391 |
Rubraca 300mg, 60 tabs/bottle |
04/01/2021 |
334.00 |
8685.00 |
08/17/2035 |
Single Source Drug |
15687 |
None |
Manufacturing costs, inflation costs, and market dynamics allow the increase to remain within market value |
None |
No change improvements |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=548, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=551 |
Product licensing was not acquired within the last 5 years. |
| Rx0000320 |
CMP Pharma |
12/31/2021 |
46287002004 |
CaroSpir spironolactone oral suspension 25mg/5ml 118ml |
10/01/2021 |
31.45 |
381.15 |
10/28/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000320 |
CMP Pharma |
12/31/2021 |
46287002001 |
CaroSpir spironolactone oral suspension 25mg/5ml 473ml |
10/01/2021 |
274.85 |
1527.85 |
10/28/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000320 |
CMP Pharma |
03/31/2021 |
46287000604 |
Sodium Polystyrene Suspension 120ml enema kit |
03/08/2021 |
7.20 |
86.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000320 |
CMP Pharma |
03/31/2021 |
46287000601 |
Sodium Polystyrene Suspension 473ml |
03/08/2021 |
12.00 |
144.60 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000320 |
CMP Pharma |
03/31/2021 |
46287000660 |
Sodium Polystyrene Suspension 60ml unit dose X 10 |
03/08/2021 |
15.80 |
191.20 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2021 |
24510011660 |
NUCYNTA ER, 100mg, tablet, 60 pack |
01/01/2021 |
82.71 |
918.17 |
09/22/2028 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $330 million since our inception. In addition, we continue to reinvest in Nucynta ER?s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Nucynta ER. |
None |
None |
1 |
02/14/2020 |
Assertio Therapeutics, Inc. |
375000000 |
None |
None |
835.46 |
760.20 |
2011 |
269.40 |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2021 |
24510017460 |
NUCYNTA ER, 150mg, tablet, 60 pack |
01/01/2021 |
106.71 |
1184.60 |
09/22/2028 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $330 million since our inception. In addition, we continue to reinvest in Nucynta ER?s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Nucynta ER. |
None |
None |
1 |
02/14/2020 |
Assertio Therapeutics, Inc. |
375000000 |
None |
None |
1077.89 |
980.79 |
2011 |
346.80 |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2021 |
24510023260 |
NUCYNTA ER, 200mg, tablet, 60 pack |
01/01/2021 |
135.46 |
1503.78 |
09/22/2028 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $330 million since our inception. In addition, we continue to reinvest in Nucynta ER?s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Nucynta ER. |
None |
None |
1 |
02/14/2020 |
Assertio Therapeutics, Inc. |
375000000 |
None |
None |
1368.32 |
1245.06 |
2011 |
441.60 |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2021 |
24510029160 |
NUCYNTA ER, 250mg, tablet, 60 pack |
01/01/2021 |
169.48 |
1881.39 |
09/22/2028 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $330 million since our inception. In addition, we continue to reinvest in Nucynta ER?s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Nucynta ER. |
None |
None |
1 |
02/14/2020 |
Assertio Therapeutics, Inc. |
375000000 |
None |
None |
1711.91 |
1557.70 |
2011 |
441.60 |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2021 |
24510005860 |
NUCYNTA ER, 50mg, tablet, 60 pack |
01/01/2021 |
44.72 |
496.46 |
09/22/2028 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $330 million since our inception. In addition, we continue to reinvest in Nucynta ER?s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Nucynta ER. |
None |
None |
1 |
02/14/2020 |
Assertio Therapeutics, Inc. |
375000000 |
None |
None |
451.74 |
411.05 |
2011 |
145.80 |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2021 |
24510010010 |
NUCYNTA, 100mg, tablet, 100 pack |
01/01/2021 |
107.78 |
1196.49 |
06/27/2025 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta, and reinvestment in the product. Nucynta is an immediate-release formulation of tapentadol that is indicated for the management of acute adult pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional, general and administrative costs associated with our operations, resulting in a deficit of over $330 Million since our inception. In addition, we continue to reinvest in Nucynta?s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Nucynta. |
None |
None |
1 |
02/14/2020 |
Assertio Therapeutics, Inc. |
375000000 |
None |
None |
1088.71 |
990.64 |
2009 |
265.00 |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2021 |
24510005010 |
NUCYNTA, 50mg, tablet, 100 pack |
01/01/2021 |
69.21 |
768.34 |
06/27/2025 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta, and reinvestment in the product. Nucynta is an immediate-release formulation of tapentadol that is indicated for the management of acute adult pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional, general and administrative costs associated with our operations, resulting in a deficit of over $330 Million since our inception. In addition, we continue to reinvest in Nucynta?s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Nucynta. |
None |
None |
1 |
02/14/2020 |
Assertio Therapeutics, Inc. |
375000000 |
None |
None |
699.13 |
636.15 |
2009 |
170.00 |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2021 |
24510007510 |
NUCYNTA, 75mg, tablet, 100 pack |
01/01/2021 |
80.87 |
897.73 |
06/27/2025 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta, and reinvestment in the product. Nucynta is an immediate-release formulation of tapentadol that is indicated for the management of acute adult pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional, general and administrative costs associated with our operations, resulting in a deficit of over $330 Million since our inception. In addition, we continue to reinvest in Nucynta?s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Nucynta. |
None |
None |
1 |
02/14/2020 |
Assertio Therapeutics, Inc. |
375000000 |
None |
None |
816.86 |
743.28 |
2009 |
199.00 |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2021 |
24510011510 |
XTAMPZA ER, 13.5mg, capsule, 100 pack |
01/01/2021 |
71.37 |
792.29 |
09/02/2036 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Xtampza ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Xtampza ER, and reinvestment in the product. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $330 million since our inception. In addition, we continue to reinvest in Xtampza ER?s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2021 |
24510012010 |
XTAMPZA ER, 18mg, capsule, 100 pack |
01/01/2021 |
90.51 |
1004.76 |
09/02/2036 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Xtampza ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Xtampza ER, and reinvestment in the product. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $330 million since our inception. In addition, we continue to reinvest in Xtampza ER?s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2021 |
24510013010 |
XTAMPZA ER, 27mg, capsule, 100 pack |
01/01/2021 |
125.91 |
1397.71 |
09/02/2036 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Xtampza ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Xtampza ER, and reinvestment in the product. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $330 million since our inception. In addition, we continue to reinvest in Xtampza ER?s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2021 |
24510014010 |
XTAMPZA ER, 36mg, capsule, 100 pack |
01/01/2021 |
154.97 |
1720.36 |
09/02/2036 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Xtampza ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Xtampza ER, and reinvestment in the product. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $330 million since our inception. In addition, we continue to reinvest in Xtampza ER?s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2021 |
24510011010 |
XTAMPZA ER, 9mg, capsule, 100 pack |
01/01/2021 |
48.49 |
538.31 |
09/02/2036 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Xtampza ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Xtampza ER, and reinvestment in the product. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $330 million since our inception. In addition, we continue to reinvest in Xtampza ER?s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000154 |
Corcept Therapeutics Incorporated |
03/31/2021 |
76346007302 |
Korlym (mifepristone) 300mg Tablets 280-ct Bottles |
03/01/2021 |
7280.00 |
154000.00 |
08/22/2038 |
Single Source Drug |
None |
1 |
Corcept is committed to discovering, developing and making available to patients and physicians medicines that treat serious disorders for which there are few ? or no ? good treatment options. In setting Korlym?s price, we weigh (i) the increased cost of administrative and commercial activities, (ii) the increased cost of discovering and developing innovative new drug candidates and (iii) our commitment that no patient be denied Korlym for financial reasons. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
WAC is reported at the package level. The information provided herein is provided to the best of our knowledge as of submission and based on our interpretation of applicable statutory and regulatory provisions. Information designated as confidential has been designated as such based on our understanding and belief that the subject information is non-public. Our provision of information shall not be interpreted as a waiver of any of our rights available under state, federal, or other applicable law with respect to the information contained herein or with respect to California SB 17, all of which we expressly reserve. Patent expiration dates do not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. |
| Rx0000154 |
Corcept Therapeutics Incorporated |
03/31/2021 |
76346007301 |
Korlym (mifepristone) 300mg Tablets 28-ct Bottles |
03/01/2021 |
728.00 |
15400.00 |
08/22/2038 |
Single Source Drug |
None |
1 |
Corcept is committed to discovering, developing and making available to patients and physicians medicines that treat serious disorders for which there are few ? or no ? good treatment options. In setting Korlym?s price, we weigh (i) the increased cost of administrative and commercial activities, (ii) the increased cost of discovering and developing innovative new drug candidates and (iii) our commitment that no patient be denied Korlym for financial reasons. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
WAC is reported at the package level. The information provided herein is provided to the best of our knowledge as of submission and based on our interpretation of applicable statutory and regulatory provisions. Information designated as confidential has been designated as such based on our understanding and belief that the subject information is non-public. Our provision of information shall not be interpreted as a waiver of any of our rights available under state, federal, or other applicable law with respect to the information contained herein or with respect to California SB 17, all of which we expressly reserve. Patent expiration dates do not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. |
| Rx0000184 |
Cosette Pharmaceuticals, Inc. |
03/31/2021 |
00713016612 |
MIGERGOT (Ergotamine Tartrate and Caffeine) Suppository, 2mg/100mg, 12 Suppositories/Pack |
02/02/2021 |
168.36 |
1853.90 |
None |
Single Source Drug |
None |
1 |
Operating primarily as a manufacturer of generic and over-the-counter drug products, the Company has a history of providing cost effective, high quality medications that help patients affected by various medical conditions. With that purpose in mind, the Company carefully and holistically evaluates and weighs a variety of factors when pricing its medications, including: maintaining accessibility and affordability of its products for both patients and payors, market conditions, the overall increase in the cost of labor and goods, the required capital investment in manufacturing facilities and systems, and most importantly, the funding of research and new product development designed to meet the needs of patients and healthcare professionals today and in the future. It is critical to note that research and new product development is a high-risk endeavor, with significant costs being incurred on medications that eventually fail due to clinical, technical or commercial reasons. By considering all of these factors in pricing decisions, the Company is taking the necessary steps to ensure the long-term availability of high quality prescription and over-the-counter drug products within its portfolio. |
None |
None |
1 |
06/28/2019 |
Horizon Therapeutics PLC |
None |
1 |
None |
70.23 |
39.96 |
1983 |
0.01 |
None |
WAC of the Product when it was introduced in 1983 is unknown. Per recommendation of Rodney Garcia, while the WAC Five Year History recites Cosette's NDC number, it actually incorporates three separate NDC numbers from the following owners: Horizon, Crealta and G&W. |
| Rx0000062 |
Covis Pharma |
03/31/2021 |
70515061001 |
Prilosec (Omeprazole Magnesium) - 30 GRANULE 10mg - Delayed Release - in 1 CARTON |
01/04/2021 |
17.99 |
377.73 |
None |
Single Source Drug |
None |
1 |
Covis Pharma's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to a) the clinical and economic value of the medicine b) the therapeutic category, market dynamics, and competitor pricing; c) discounts provided to customers in the public and private sectors; and d) patient support provided by Covis Pharma to ensure patient access. |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
04/01/2017 |
AstraZeneca |
None |
1 |
None |
195.97 |
195.97 |
2003 |
195.07 |
None |
WAC at Intro to Market is unavailable so the earliest date in which WAC is known (i.e., 2015) has been entered. |
| Rx0000062 |
Covis Pharma |
03/31/2021 |
70515062501 |
Prilosec (Omeprazole Magnesium) - 30 GRANULE 2.5 mg- Delayed Release - in 1 CARTON |
01/04/2021 |
17.99 |
377.73 |
None |
Single Source Drug |
None |
1 |
Covis Pharma's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to a) the clinical and economic value of the medicine b) the therapeutic category, market dynamics, and competitor pricing; c) discounts provided to customers in the public and private sectors; and d) patient support provided by Covis Pharma to ensure patient access. |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
04/01/2017 |
AstraZeneca |
None |
1 |
None |
195.97 |
195.97 |
2003 |
195.07 |
None |
WAC at Intro to Market is unavailable so the earliest date in which WAC is known (i.e., 2015) has been entered. |
| Rx0000230 |
Cumberland Pharmaceuticals |
03/31/2021 |
66220028708 |
Caldolor (ibuprofen) injection 800 mg/8ml for intravenous use; sold by the tray (25 vials/ tray) |
01/21/2021 |
26.02 |
459.80 |
09/14/2030 |
Single Source Drug |
1774383 |
None |
Our cost of goods and manufacturing is based on forecasted demand. If our PO's are less than we submit to our contract manufacturer, they raise their prices to us. Also, as the cost of manufacturing and raw materials increase, the price of product will subsequently increase |
None |
not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired within the last 5 years |
| Rx0000230 |
Cumberland Pharmaceuticals |
03/31/2021 |
66220028422 |
Caldolor prefilled IV bag (ibuprofen) 800mg/ 200ml is a nonsteroidal anti-inflammatory drug (NSAID) sold by the case of 20 premixed IV bags |
01/21/2021 |
116.58 |
416.58 |
09/30/2029 |
Single Source Drug |
2091074 |
None |
Our cost of goods and manufacturing is based on forecasted demand. If our PO's are less than we submit to our contract manufacturer, they raise their prices to us. Also, as the cost of manufacturing and raw materials increase, the price of product will subsequently increase |
None |
not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired within the last 5 years |
| Rx0000230 |
Cumberland Pharmaceuticals |
03/31/2021 |
66220071930 |
Lactulose 10 GM Packet for oral solution 30 EA UD |
01/21/2021 |
11.62 |
243.95 |
12/18/2031 |
Single Source Drug |
7678082 |
None |
Our cost of goods and manufacturing is based on forecasted demand. If our PO's are less than we submit to our contract manufacturer, they raise their prices to us. Also, as the cost of manufacturing and raw materials increase, the price of product will subsequently increase |
None |
not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired within the last 5 years |
| Rx0000230 |
Cumberland Pharmaceuticals |
03/31/2021 |
66220072930 |
Lactulose 20 GM Packet for oral solution 30 EA UD |
01/21/2021 |
12.03 |
252.79 |
12/18/2031 |
Single Source Drug |
7679507 |
None |
Our cost of goods and manufacturing is based on forecasted demand. If our PO's are less than we submit to our contract manufacturer, they raise their prices to us. Also, as the cost of manufacturing and raw materials increase, the price of product will subsequently increase |
None |
not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired within the last 5 years |
| Rx0000230 |
Cumberland Pharmaceuticals |
03/31/2021 |
66220031522 |
Telavancin HCl 750 MG Solution Reconstituted 1 EA UD sold in cases of 12 vials per case |
01/21/2021 |
19.64 |
510.80 |
01/01/2027 |
Single Source Drug |
14976477 |
None |
Our cost of goods and manufacturing is based on forecasted demand. If our PO's are less than we submit to our contract manufacturer, they raise their prices to us. Also, as the cost of manufacturing and raw materials increase, the price of product will subsequently increase |
None |
not applicable |
None |
11/12/2018 |
Theravance Biopharma, Inc |
25000000 |
None |
None |
431.91 |
412.28 |
2009 |
374.94 |
None |
None |
| Rx0000230 |
Cumberland Pharmaceuticals |
06/30/2021 |
66220031522 |
Telavancin HCl 750 MG Solution Reconstituted 1 EA UD sold in cases of 12 vials per case |
06/10/2021 |
153.25 |
6282.84 |
01/01/2027 |
Single Source Drug |
34020 |
None |
Our cost of goods and manufacturing is based on forecasted demand. If our PO's are less than we submit to our contract manufacturer, they raise their prices to us. Also, as the cost of manufacturing and raw materials increase, the price of product will subsequently increase |
None |
not applicable |
None |
11/12/2018 |
Theravance Biopharma, Inc |
25000000 |
None |
None |
431.91 |
412.28 |
2009 |
374.94 |
None |
None |
| Rx0000230 |
Cumberland Pharmaceuticals |
03/31/2021 |
66220016010 |
Vaprisol (conivaptan hydrochloride) 20mg/ 100 ml for intravenous use: sold in multiples of 10 cartons/case |
01/21/2021 |
66.02 |
891.32 |
12/15/2019 |
Single Source Drug |
1745863 |
None |
Our cost of goods and manufacturing is based on forecasted demand. If our PO's are less than we submit to our contract manufacturer, they raise their prices to us. Also, as the cost of manufacturing and raw materials increase, the price of product will subsequently increase. |
None |
not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired within the last five years |
| Rx0000181 |
Currax Pharmaceuticals LLC |
03/31/2021 |
51267089099 |
Contrave Oral Tablet 120ct (naltrexone HCI/bupropion HCI) 8-90mg |
02/16/2021 |
25.61 |
303.60 |
07/20/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/26/2019 |
Nalpropion Pharmaceuticals LLC |
0 |
None |
The same private equity investor owned Currax Pharmaceuticals LLC and Nalpropion Pharmaceuticals LLC and merged the two companies. |
277.99 |
277.99 |
2014 |
199.50 |
None |
The same private equity investor owned Currax Pharmaceuticals LLC and Nalpropion Pharmaceuticals LLC and merged the two companies. |
| Rx0000181 |
Currax Pharmaceuticals LLC |
03/31/2021 |
42847031108 |
Onzetra Xsail Nasal Exhaler Powder 4 Dose Kit (sumatriptan succinate exhale powder) 11mg |
02/16/2021 |
69.60 |
940.00 |
10/20/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/25/2019 |
Avanir Pharmaceuticals |
4480000 |
None |
None |
792.00 |
792.00 |
2016 |
488.00 |
None |
For the sake of clarity, Currax Pharmaceuticals LLC is providing the five year history as required by the regulation and based upon pricing history as provided by MediSpan. Currax Pharmaceuticals LLC, as manufacturer, are filling orders only for the Currax NDC-42847031108, the former (Avanir) NDC-64597031108 is still in the market place and may be ordered by pharmacies from their wholesalers. |
| Rx0000181 |
Currax Pharmaceuticals LLC |
03/31/2021 |
42847010330 |
Silenor Oral Tablet 30ct (doxepin hydrochloride) 3mg |
02/16/2021 |
39.90 |
538.80 |
09/27/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/30/2019 |
Pernix Therapeutics Holdings, Inc. |
79600000 |
None |
The acquisition price reflects the total assets purchased out of bankruptcy - not limited to this single NDC. |
453.98 |
428.28 |
2010 |
165.14 |
None |
Currax Pharmaceuticals LLC dba Cypress, Hawthorn and Macoven, acquired asset out of bankruptcy on April 30, 2019 from Pernix Therapeutics Holdings, Inc. All pricing history prior to April 30, 2019 is not Currax Pharmaceuticals LLC's history. For the sake of clarity, Currax Pharmaceuticals LLC is providing the five year history as required y the regulation and based upon pricing history as provided by MediSpan. Currax Pharmaceuticals LLC accepts no liability for pricing and pricing history prior to April 30, 2019.
This product was acquired along with several other products in a bankruptcy acquisition. The purchase amount for this specific product is not reported. |
| Rx0000181 |
Currax Pharmaceuticals LLC |
03/31/2021 |
42847010630 |
Silenor Oral Tablet 30ct (doxepin hydrochloride) 6mg |
02/16/2021 |
39.90 |
538.80 |
09/27/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/30/2019 |
Pernix Therapeutics Holdings, Inc. |
79600000 |
None |
The acquisition price reflects the total assets purchased out of bankruptcy - not limited to this single NDC. |
453.98 |
428.28 |
2010 |
165.14 |
None |
Currax Pharmaceuticals LLC dba Cypress, Hawthorn and Macoven, acquired asset out of bankruptcy on April 30, 2019 from Pernix Therapeutics Holdings, Inc. All pricing history prior to April 30, 2019 is not Currax Pharmaceuticals LLC's history. For the sake of clarity, Currax Pharmaceuticals LLC is providing the five year history as required y the regulation and based upon pricing history as provided by MediSpan. Currax Pharmaceuticals LLC accepts no liability for pricing and pricing history prior to April 30, 2019.
This product was acquired along with several other products in a bankruptcy acquisition. The purchase amount for this specific product is not reported. |
| Rx0000181 |
Currax Pharmaceuticals LLC |
03/31/2021 |
42847085009 |
Treximet 9 tab/pk (sumatriptan/naproxen) 85 mg/500 mg |
02/16/2021 |
93.42 |
1261.53 |
04/02/2026 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/30/2019 |
Pernix Pharmaceuticals |
79600000 |
None |
The acquisition price reflects the total assets purchased out of bankruptcy - not limited to this single NDC. |
967.23 |
880.09 |
2015 |
625.00 |
None |
Currax Pharmaceuticals LLC dba Cypress, Hawthorn and Macoven, acquired asset out of bankruptcy on April 30, 2019 from Pernix Therapeutics Holdings, Inc. All pricing history prior to April 30, 2019 is not Currax Pharmaceuticals LLC's history. For the sake of clarity, Currax Pharmaceuticals LLC is providing the five year history as required y the regulation and based upon pricing history as provided by MediSpan. Currax Pharmaceuticals LLC accepts no liability for pricing and pricing history prior to April 30, 2019.
This product was acquired along with several other products in a bankruptcy acquisition. The purchase amount for this specific product is not reported. |